Benzinga | Aug 9, 2021 04:14PM EDT

Adamas Pharmaceuticals Q2 EPS $(0.27) Beats $(0.29) Estimate, Sales $22.00M Beat $21.95M Estimate

Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 27.03 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $22.00 million which beat the analyst consensus estimate of $21.95 million by 0.23 percent. This is a 17.06 percent increase over sales of $18.79 million the same period last year.